EN
新闻动态
NEWS
Position:
Homepage
/
/
2015.3

2015.3

  • Categories:发展历程
  • Author:
  • Origin:
  • Time of issue:2015-03-01
  • Views:0

(Summary description)In March 2015, with a valuation of 250 million yuan and a financing of 150 million yuan, it became an enterprise under the top 500 Yatai Group in China. In June 2015, it initiated the phase I clinical trial of Vicagrelor. In January, the phase I clinical trial of Vicagrelor was completed.

2015.3

(Summary description)In March 2015, with a valuation of 250 million yuan and a financing of 150 million yuan, it became an enterprise under the top 500 Yatai Group in China. In June 2015, it initiated the phase I clinical trial of Vicagrelor. In January, the phase I clinical trial of Vicagrelor was completed.

  • Categories:发展历程
  • Author:
  • Origin:
  • Time of issue:2015-03-01
  • Views:0
Information

In March 2015, with a valuation of 250 million yuan and a financing of 150 million yuan, it became an enterprise under the top 500 Yatai Group in China. In June 2015, it initiated the phase I clinical trial of Vicagrelor. In January, the phase I clinical trial of Vicagrelor was completed.

Scan the QR code to read on your phone

Previous: 2015.6
Next: 2014.2
Previous: 2015.6
Next: 2014.2

Relevant news

Previous page
1
2
这是描述信息

Contact Us

Add:No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

这是描述信息

Scan to see

Copyright © Jiangsu Vcare PharmaTech Co. Ltd.,

中兴能源